JAZZ Jazz Pharmaceuticals plc

136.5
+5.19  (+4%)
Previous Close 131.31
Open 131.9
Price To Book 2.85
Market Cap 7,785,352,848
Shares 57,035,552
Volume 686,955
Short Ratio
Av. Daily Volume 517,625

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 26, 2019 met primary endpoint.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
JZP-6
Fibromyalgia
Phase 2 enrollment initiation announced February 8, 2017.
JZP-110
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Xyrem
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
FDA Approval announced March 20, 2019.
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3 interim analysis due 2019.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Vyxeos
Acute myeloid leukemia
Phase 2 enrolment to be completed 2019.
Defibrotide
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
JZP-258
Idiopathic Hypersomnia
Phase 1/2 presentation at ASCO May 31, 2019.
CPX-351
Acute myeloid leukemia (AML)